Skip to main content
. 2023 Apr 17;31(7):2105–2119. doi: 10.1016/j.ymthe.2023.04.008

Figure 6.

Figure 6

CXCR2 blockade enhanced efficacy of EpCAM CAR-T cells by impairing MDSC accumulation within the tumor site

(A) Treatment scheme. (B) Left: tumor growth curve of all groups. Right: tumor growth curve of combination groups (n = 7–9 mice pooled). (C) Kaplan-Meier survival curve of 4T1 tumor-bearing mice (n = 11 mice per group). Log rank test. (D) Weight change curve of mice bearing 4T1 tumors (n = 7–9). (E) Representative multicolor immunofluorescence images of tumor from different groups (n = 3; scale bar: 100 μm). CD11b+ cells (red arrowheads) and T cells (white arrowheads). Bar plot showing fractions of CD3+ cells and CD11b+ cells (percentage of total cells) in the tumor. Cell quantification by Halo version 3.6 (unpaired Student’s t test). (F) CAR gene copies in tumor tissue at day 3 after EpCAM CAR-T cell infusion (n = 5). (G) Left: tumor growth curve. Right: weight change curve (n = 7 mice pooled). Results are presented as mean ± SEM. ∗∗p < 0.01; NS, p > 0.05 (mixed-effects analysis).